LINDERS
NOTARISSEN

Seen for the legalisation of the signature of Mr. J.A. Bouman, by me
Mr. LUCAS JACOBUS MARIA TEUNISSEN, civil law notary, residing at Breda
(The Netherlands), on the twenty-second day of January two thousand eighteen.

Mr. L.J.M. Teunissen, *civil law notary*

Mr. L.J.M. TEUNISSEN
NOTARIS TE BREDA

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: THE NETHERLANDS
   This public document
2. has been signed by **mr. L.J.M. Teunissen**
3. acting in the capacity of notary at Breda
4. bears the seal/stamp of aforesaid notary

Certified

5. in Breda
6. on 23-01-2018
7. by the registrar of the district court of Zeeland-West-Brabant
8. no. 18/346

9. Seal/stamp:
10. Signature:

M.D.M. van Agtmaal

Kantooradres:
Ginnekenweg 188
4835 NH Breda

Postadres:
Postbus 4618
4803 EP Breda

T 076-565 28 50 F 076-565 20 70
E info@lindersnotarissen.nl
www.lindersnotarissen.nl

KvK nummer 20165175
Algemene voorwaarden*
en bankrelaties: z.o.z.

POWER OF AUTHORIZATION

The undersigned: Amgen Europe B.V., a company duly incorporated and existing under the laws of the Netherlands, registered with the Trade Register under registration no. 20080576, headquartered in Minervum 7061, Breda, PO Box 3345, 4800 DH Breda, the Netherlands hereinafter also referred to "the Marketing Authorization Holder" or "MAH", represented by its directors registered at the chamber of commerce, Netherlands.

Amgen Europe B.V. is formally holding the Marketing Authorization for various medicinal products for the benefit of Amgen (Europe) GmbH, i.e. is acting as MAH. The present PoA refers to:

- Aranesp®
- Blincyto®
- Kyprolis®
- Mimpara®
- Neulasta®
- Neupogen®
- Nplate®
- Prolia®
- Repatha®
- Vectibix®
- Xgeva®
- Parsabiv®
- Imlygic®
- AMGEVITA™
- KANJINTI™

as well as any and all other medicinal products whose production is in progress or whose Marketing Authorization has been obtained for the term of validity of this PoA (hereinafter referred to as the "Products").

HEREBY AUTHORIZES

Amgen s.r.o., with registered address in Prague 1, Klimentská 1216/46, Postal Code 110 02, Business ID No.: 271 17 804, incorporated under the laws of the Czech Republic duly represented by its directors registered at the chamber of commerce, to represent Amgen Europe B.V. in its

capacity as MAH of the Products and as specifically required under applicable local legal or regulatory rules and regulations before all National Regulatory Authorities in the Czech Republic; with respect to regulatory and pharmacovigilance matters including activities in connection with local registrations, tender activities, submissions and/or reporting, as well as for the purpose of compliance with the obligations of MAH pursuant to section 77(1)(h) of the Czech Act No. 378/2007 Coll., on Pharmaceuticals. *Further Amgen s.r.o. is entitled to negotiate and act in respect to the negotiation with the Reimbursement of Medicinal Product executed between the MAH and various Health Insurance Companies.*

The afore-mentioned list of representation tasks and rights is exhaustive. Amgen s.r.o. will - at all times - act in its own name. The MAH has supervisory rights upon the activities performed under this PoA. Amgen s.r.o., does require formal prior approval of MAH or Amgen (Europe) GmbH in case any action impacts either entity in its rights or obligations, i.e. in such case Amgen s.r.o. position is limited to execution of activities as required under local legal or regulatory rules or regulations. For the avoidance of doubt, Amgen s.r.o. at no time can formally nor contractually bind MAH or any other entity based on this PoA.

This PoA does not grant decision-making authority for or on behalf of the MAH or Amgen (Europe) GmbH. All actions of the proxies intended to exercise this PoA are of mere executing character. The proxies are required to strictly follow and implement all internal processes and instructions of the MAH. This PoA does not cover the authority to bind the MAH in contracts with regulatory authorities or other third parties. The proxies are not entitled to sub-authorize third parties with all or part of the powers granted hereby.

The present PoA shall be subject of the Laws of The Netherlands and shall be valid at the date executed and may be revoked at any time. It replaces all prior given Power of Authorizations for the same subject.

Breda, 17 JAN 2018

Amgen Europe B.V

Represented by Jan Bouman

Title: Director & Executive Director Site Operations